Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

New Haven BIZ special highlights local leaders

A special edition of New Haven BIZ spotlights local leaders facing pivotal times. Mentioned in the article are many friends, sponsors, and members of BioCT,...

| By Kelley Gipson

Record NSF grant to UConn School of Medicine

The U.S. National Science Foundation (NSF) has awarded the University of Connecticut a $40 million research grant award, the largest in the University’s history, to...

| By Kelley Gipson

Bioasis reports stock options, appointment

Bioasis Technologies reports that it has granted stock options to acquire a total of 1,367,606 common shares effective June 30, 2020. The company also announced the...

| By Kelley Gipson

Yale pilot grants to study resources for women

Attention to research on women’s health remains far behind that of men, and fewer women faculty are pursuing opportunities to commercialize their research. Two organizations...

| By Kelley Gipson

New Haven’s Rallybio raises over $90 million in IPO

New Haven-based biotech Rallybio, founded by three former Alexion executives, pulled in nearly $93 million in its recent IPO. Rallybio is developing drugs for the treatment...

| By Kelley Gipson

BioCT welcomes Eleanore Seibert to Board of Directors

BioCT welcomes Eleanore Seibert, PhD to its Board of Directors. Eleanore is Vice President of Drug Metabolism and Pharmacokinetics within the Research and Development organization at Boehringer...

| By Kelley Gipson

Pierce names new lab director and new president

The John B. Pierce Laboratory, a nonprofit, independent research institute affiliated with Yale University, recently named a new laboratory director and the first female president...

| By Kelley Gipson

Enko partners with Bayer on crop protection

Enko has announced details on its partnership with Bayer to develop diverse chemistries for crop protection. Applying drug discovery approaches from pharma to crop protection...

| By Kelley Gipson

Branford-based IsoPlexis considers IPO

Branford-based medical technology company IsoPlexis is looking to go public. Founded by Yale students in 2013, the company has developed technology that can help doctors develop...

| By Kelley Gipson

Thetis pancreatic cancer treatment is ‘orphan drug’

The FDA has designated Thetis Pharmaceuticals’ experimental treatment for pancreatic cancer an “orphan drug,” a label that makes the company eligible for tax credits and other...